inflammatory bowel disease
AbbVie and FutureGen announce license agreement for IBD therapy
June 14, 2024Research and Development FutureGen, Gastrointestinal tract, ibd, inflammatory bowel disease
AbbVie and FutureGen Biopharmaceutical have announced a license agreement for the development of FG-M701, a next-generation TL1A antibody for the …
Sosei Heptares doses first patient in trial for inflammatory bowel disease treatment
March 21, 2024Research and Development Gastrointestinal tract, Sosei Heptares, clinical trial, inflammatory bowel disease, phase 1 trial
Sosei Heptares has announced that it has dosed the first patient in its phase 1 trial assessing a novel EP4 …
Pfizer invests $25m in Vedanta BioSciences’ IBD treatment
January 13, 2021Research and Development Pfizer, Vedanta Biosciences, inflammatory bowel disease
Pfizer has invested $25 million in Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases, …
Latest content
Global coalition calls for stronger government action on COPD
September 18, 2026
Global health researchers call for more equitable partnerships
September 17, 2026
Liverpool launches £20m lab for infectious disease drug discovery
September 16, 2026
Circle Health Group expands into UK laboratory operations
September 15, 2026
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
September 14, 2026
